The strategy with an average of two acquisitions per year should be continued, said Sartorius CEO Joachim Kreuzburg of the German Press Agency. “We are constantly analyzing possible acquisition candidates.” Through them, the company gains know-how.
“We don’t buy big companies to buy market shares,” said Kreuzburg. “Instead, we aim to add technologies that broaden our range and make us even more relevant for our customers.” The general aim is to speed up the development and manufacture of medicines and to reduce the costs involved. Among other things, it is about accelerating test procedures for new active ingredients, for example through automation. “Today this is only possible to a very limited extent.”
The head of the DAX group was surprised at how well corporate takeovers would have worked for Sartorius, even in times of crisis. Even in times of recurring lockdowns, the takeovers and the first steps towards integration have been successful.
The Sartorius preferred share temporarily fell by 4.82 percent to EUR 351.60 in XETRA trading on Monday.
/xma/DP/jha
GOETTINGEN (dpa-AFX)
Leverage must be between 2 and 20
No data
More news about Sartorius AG Vz.
Image sources: T. Schneider / Shutterstock.com
